Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Arbutus Biopharma Corp (NQ: ABUS ) 3.870 +0.040 (+1.04%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Arbutus Biopharma Corp < Previous 1 2 3 4 5 6 Next > Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update March 02, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update February 16, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus to Participate in Three Upcoming Investor Conferences February 06, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Biopharma's Return On Capital Employed Insights December 12, 2022 Via Benzinga Recap: Arbutus Biopharma Q2 Earnings August 04, 2022 Arbutus Biopharma (NASDAQ:ABUS) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Via Benzinga Arbutus Biopharma: Q1 Earnings Insights May 05, 2022 Arbutus Biopharma (NASDAQ:ABUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Via Benzinga Arbutus Announces Resignation of Board Member January 27, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Announces 2023 Corporate Objectives and Provides Financial Update January 05, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection December 13, 2022 From Arbutus Biopharma Corporation Via GlobeNewswire Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims December 06, 2022 Via Benzinga Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update November 09, 2022 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus to Present at Jefferies London Healthcare Conference November 08, 2022 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting® November 01, 2022 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022 October 31, 2022 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update October 26, 2022 From Arbutus Biopharma Corporation Via GlobeNewswire Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End September 30, 2022 From Arbutus Biopharma Corporation Via GlobeNewswire Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday September 13, 2022 Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares! Via InvestorPlace Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know August 26, 2022 Moderna Inc (NASDAQ: MRNA) has Via Benzinga Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate August 04, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners July 21, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot July 06, 2022 The company isn't seeking an injunction, but wants "fair compensation." Via Investor's Business Daily Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot July 05, 2022 The company isn't seeking an injunction, but wants "fair compensation." Via Investor's Business Daily This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B June 28, 2022 Via Benzinga Morning Brief: Top Financial Stories Dominating on Monday, May 9 May 09, 2022 CNBC Ford Motor Selling 8M Shares Of Rivian Automotive Via Benzinga Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ May 09, 2022 Moderna Inc (NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 vaccine, arguing that the companies may only pursue their claims by seeking... Via Benzinga The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study May 05, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Arbutus Biopharma Earnings Conference Call Is Coming Up, Here's What You Need To Know April 28, 2022 Arbutus Biopharma (NASDAQ:ABUS) will host a conference call at 08:45 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. Via Benzinga Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters March 18, 2022 Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents, Via Benzinga Arbutus Biopharma Earnings Perspective: Return On Capital Employed March 09, 2022 Benzinga Pro data, Arbutus Biopharma (NASDAQ:ABUS) reported Q4 sales of $3.21 million. Earnings fell to a loss of $21.32 million, resulting in a 11.29% decrease from last quarter... Via Benzinga Arbutus Biopharma: Q4 Earnings Insights March 03, 2022 Arbutus Biopharma (NASDAQ:ABUS) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.... Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.